MSD (Italia) s.r.l.

What MSD (Italia) s.r.l. does

MSD (Italia) S.r.l. is the wholly-owned Italian subsidiary of Merck & Co., Inc. (NYSE: MRK), operating under the MSD brand used outside the United States and Canada. The company commercializes a portfolio of pharmaceutical products and vaccines across seven therapeutic areas: oncology (including the PD-1 inhibitor Keytruda/pembrolizumab), vaccines (anti-HPV 9-valent, Vaxneuvance 15-valent and 21-valent pneumococcal conjugates), infectious diseases, chronic non-communicable diseases, anesthesia, immunology, and cardiometabolic/respiratory diseases. With 501-1,000 employees and headquarters in Rome, MSD Italia distributes products through the Italian National Health Service framework, hospital and retail pharmacies, and direct supply to healthcare institutions, with pricing negotiated through regulatory channels rather than market mechanisms.

The technology base is anchored in Merck & Co.'s global R&D infrastructure, which invests nearly USD 16 billion annually in 2025, employs 23,500 researchers, and maintains approximately 30 molecules in Phase 3 development. Local capabilities are reinforced through the USD 200 million, 10-year partnership with BSP Pharmaceuticals S.p.A. for the production of oncological biotechnological drugs in Italy, and through public-private research collaborations with institutions including Fondazione IRCCS Istituto Nazionale dei Tumori di Milano and Politecnico di Milano for lung cancer care pathway innovation.

The company operates a B2B field-sales go-to-market targeting healthcare professionals, hospitals, and institutional buyers, with revenue derived from one-time product licensing/sales through regulated Italian healthcare distribution. President and CEO Nicoletta Luppi has led the subsidiary since 2015 and additionally serves as President of Vaccines Europe and Vice President of Assolombarda. The company has accumulated 16 Prix Galien Italia awards since 1992 and maintains certifications including Top Employer Italia (9 consecutive years), Great Place to Work (5+ consecutive years), gender equality certification (UNI/PdR 125:2022), GDPR compliance, and WCAG 2.1 AA digital accessibility. CSR initiatives include MSD CrowdCaring crowdfunding (EUR 820,000+ raised since 2018), MSD for Mothers (USD 650 million invested globally since 2011), and over EUR 2 million in COVID-19 solidarity donations.

Name

MSD (Italia) s.r.l.

Legal name

MSD Italia S.r.l.

Website

https://msd-italia.it

Company type

Private

Founded year

1956

Operating status

Operating

Headcount range

501–1,000 employees

Short description

MSD (Italia) S.r.l. is the Italian subsidiary of Merck & Co., commercializing pharmaceuticals and vaccines across oncology, vaccines, infectious diseases, immunology, anesthesia, and cardiometabolic/respiratory therapeutic areas to the Italian National Health Service, hospitals, and healthcare professionals.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM)

akta.pro secondary industries

Vaccine Cold Chain, Storage & Distribution (HLAIAEAK), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Vaccines & Public Health Product Distribution (CRAOAHAI)

Keywords

• Pharmaceutical products
• Vaccines and biologics
• Oncology therapeutics
• Infectious disease treatments
• Biopharmaceutical research

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sale of proprietary pharmaceutical products and vaccines across therapeutic areas including oncology, vaccines, infectious diseases, immunology, anesthesia, and cardiometabolic conditions

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels8 records

Core offering

MSD (Italia) s.r.l. researches, develops, manufactures, and commercializes proprietary pharmaceutical medicines and vaccines across seven therapeutic areas: oncology, vaccines, infectious diseases, chronic non-communicable diseases, anesthesia, immunology, and cardiometabolic and respiratory diseases. The company distributes these products through Italy's regulated National Health Service channels to hospitals, pharmacies, and healthcare professionals, operating as the Italian subsidiary of Merck & Co., Inc.

Product overview

MSD (Italia) s.r.l. is the Italian subsidiary of Merck & Co. (known as MSD outside the US and Canada), a global pharmaceutical company with over 130 years of history. The company operates as a research-intensive biopharmaceutical company with a pipeline ranked among the most promising, featuring approximately 30 molecules in Phase 3 development and annual R&D investments of nearly 16 billion USD (2025) with 23,500 researchers. The portfolio includes pharmaceutical products and vaccines across seven major therapeutic areas: Oncology (including Keytruda/pembrolizumab), Vaccines (including anti-HPV vaccine, Vaxneuvance/pneumococcal conjugate vaccines, and LAGEVRIO/molnupiravir), Infectious Diseases, Chronic Non-Communicable Diseases, Anesthesia, Immunology, and Cardiometabolic and Respiratory Diseases. The company also operates CSR programs including MSD CrowdCaring (crowdfunding), MSD for Mothers (maternal health), and Mectizan Donation Program (river blindness treatment).

Differentiator

Problem solved

Functional benefit

Products and services

• Keytruda (Pembrolizumab) Humanized monoclonal antibody (anti-PD-1) used as standard of care in numerous oncological indications, both in palliative and potentially curative contexts. Indicated for treating multiple cancer types including lung cancer.
• Anti-HPV Vaccine (9-valent) Vaccine protecting against 9 HPV types responsible for 90% of cervical cancers, precancerous lesions, and genital warts. Supports the WHO and European/national cancer plan goal of 90% HPV vaccination coverage by 2030.
• Vaxneuvance (Pneumococcal Conjugate Vaccine 15-valent) Pneumococcal polysaccharide conjugate vaccine (15-valent) indicated for active immunization against invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae in infants, children, adolescents (6 weeks to under 18 years) and adults 18 years and older.
• Pneumococcal Conjugate Vaccine 21-valent Vaccine approved for prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae. Expands coverage for pneumococcal disease prevention beyond earlier valents.
• Sotatercept Orphan drug for treatment of adult patients with pulmonary arterial hypertension (PAH). Addresses unmet medical needs in rare cardiovascular/respiratory disease treatment.
• LAGEVRIO (Molnupiravir) Oral antiviral medication (orange capsule) for treatment of COVID-19. Analogous ribonucleoside that inhibits SARS-CoV-2 replication. Approved or authorized in over 25 countries.
• Mectizan (Ivermectin) Antiparasitic medication donated through the Mectizan Donation Program for onchocerciasis (river blindness) control. Donated since 1987 with over 4.4 billion treatments provided to date.
• Anesthesia Pharmaceuticals Range of drugs used in general anesthesia developed and commercialized by MSD to support anesthesiologist-intensivists in ensuring patient safety during anesthesiological procedures.

Quantifiable outcome

• Over 30 million women reached through MSD for Mothers program in 65 countries
• +4 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

20 partnerships are on record, tiered minor and core.

• NABA - Nuova Accademia di Belle ArtiminorStrategic or Co-development Partner · 10 February 2026Collaboration for CAREmotions project - three short films on mental health, healthy lifestyles, and prevention for young people. Students from NABA's Cinema and Animation program created the films with scientific supervision from Professor Andrea Grignolio.
• Sapienza Universita di RomaminorStrategic or Co-development Partner · 21 May 2025Patronage partnership for 'Investing for Future. Donne e STEAM: da gap a plus' project promoting female participation in STEM disciplines with Lorenzo Quinn sculpture 'Urania's passion' displayed at university.
• AIPI - Associazione Ipertensione Polmonare ItalianaminorStrategic or Co-development Partner · 12 December 2024Patronage partnership for 'Al Cuore del Respiro' campaign to raise awareness about pulmonary arterial hypertension.
• AMIP - Associazione Malati di Ipertensione PolmonareminorStrategic or Co-development Partner · 12 December 2024Patronage partnership for 'Al Cuore del Respiro' campaign to raise awareness about pulmonary arterial hypertension.
• Fondazione IRCCS Istituto Nazionale dei Tumori di MilanocoreStrategic or Co-development Partner · 8 October 2024Public-private partnership for improving oncology patient care. MSD Italia contributes know-how, organizational capabilities, and technical-scientific expertise to design an innovative model for optimizing lung cancer patient management and care pathways.
• Politecnico di Milano - School of ManagementcoreStrategic or Co-development Partner · 8 October 2024Collaboration in public-private partnership for oncology patient management, bringing academic management expertise and process innovation to lung cancer patient care pathways.
• Fondazione MSDcoreStrategic or Co-development Partner · 23 January 2024MSD Foundation supporting innovative health projects and social initiatives including the CAREmotions project with NABA for youth health awareness through creative arts, and various patient support and prevention programs.
• BSP Pharmaceuticals S.p.A.coreStrategic or Co-development Partner · 31 May 2023Partnership for production of oncological biotechnological drugs. MSD invested 200 million USD over 10 years as part of this collaboration, representing the first concrete response to the Italian Government's pharmaceutical table created by the Ministries of Enterprise and Health. The partnership generates approximately 100 employee positions and 5 million EUR annually in satellite activities.
• Retake RomaminorStrategic or Co-development Partner · 25 May 2022Environmental and community volunteering partnership for urban regeneration. Activities include beach cleanup (collecting nearly 2 tons of waste), school renovation, and civic responsibility initiatives involving MSD employees.
• SIAARTI (Societa Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva)minorStrategic or Co-development Partner · 20 May 2022Patronage partnership for '#Oltreilbuio' educational campaign addressing anesthesia fear and patient information.
• Comunita di Sant'EgidiominorStrategic or Co-development Partner · 21 April 2022Support for Ukrainian refugee assistance program including first reception, accommodation, essential goods distribution, and integration pathways for approximately 50 refugees over three months.
• CUAMM Medici con l'AfricaminorStrategic or Co-development Partner · 21 April 2022Support for Ukrainian refugee healthcare assistance including COVID-19 rapid screening, vaccination information, and referral services for Ukrainian refugees arriving in Italy.
• EMA Roma (Donatori Volontari Sangue)minorStrategic or Co-development Partner · 26 October 2021Blood donation initiative partnership with EMA Roma mobile unit hosted at MSD Italia headquarters to enable employees to donate blood at the San Filippo Neri hospital.
• Croce Rossa ItalianaminorStrategic or Co-development Partner · 11 June 2020COVID-19 emergency support with 650,000 EUR donation to enhance response capabilities through field hospitals and pre-triage tents.
• FIMMG (Federazione Italiana Medici di Medicina Generale)minorStrategic or Co-development Partner · 11 June 2020COVID-19 support with 80,000 masks donated to enable safe patient visits at family doctor offices.
• CittadinanzAttivaminorStrategic or Co-development Partner · 11 June 2020COVID-19 support with 80,000 masks donated to assist people in difficulty through volunteer organization.
• EppelacoreStrategic or Co-development Partner · 23 January 2018Crowdfunding platform hosting MSD CrowdCaring initiative for innovative health and inclusion projects. Over 820,000 EUR raised since 2018 with MSD co-financing of 350,000 EUR, enabling 80 projects across Italy through the 'financing from below' model.
• Vaccines EuropecoreStrategic or Co-development PartnerMSD Italia President Nicoletta Luppi serves as President of Vaccines Europe, the reference group for vaccines and immunization within EFPIA representing vaccine industry voice in Europe since 1991.
• AssolombardaminorStrategic or Co-development PartnerMSD Italia President Nicoletta Luppi serves as Vice President with delegation to 'Europe and Life Sciences', contributing to industry policy discussions.
• FarmindustriaminorStrategic or Co-development PartnerMSD Italia President Nicoletta Luppi serves as Coordinator of Prevention group and invited member of Presidential Committee, representing pharmaceutical industry interests in Italy.

Scale indicators16 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• AbbVie Italia: Italian subsidiary of AbbVie Inc., a research-focused biopharma with leading positions in immunology (Humira/Skyrizi/Rinvoq) and oncology. Comparable in immunology franchise depth and hospital/specialty GTM in Italy.
• AstraZeneca Italia: Italian subsidiary of AstraZeneca plc, a science-led biopharma spanning oncology, biopharmaceuticals (rare disease), and vaccines/immune therapies. Comparable in research intensity, oncology pipeline, and respiratory franchise.
• Bristol-Myers Squibb Italia: Italian operations of Bristol-Myers Squibb Company, an oncology and immunology-focused biopharma. Comparable in immuno-oncology portfolio (directly competing with Keytruda via Opdivo), hospital-channel GTM, and Italian SSN commercialization.
• Roche Italia: Italian operations of F. Hoffmann-La Roche, a global biopharma with strong oncology and diagnostics franchises. Closely comparable in oncology portfolio depth, hospital-channel GTM, and Italian SSN commercialization approach.
• GSK Italia: Italian subsidiary of GSK plc, one of the world's leading vaccine manufacturers with strong respiratory, HIV, and oncology franchises. Directly comparable as a primary competitor in the HPV and pneumococcal vaccine categories in Italy.
• Eli Lilly Italia: Italian subsidiary of Eli Lilly and Company, a research-intensive biopharma with oncology, immunology, diabetes, and neuroscience franchises. Comparable in R&D intensity, SSN commercialization, and therapeutic-area breadth.
• Sanofi Italia: Italian operations of Sanofi S.A., a major vaccines and specialty-care player with deep Italian presence. Directly comparable in vaccines franchise, immunology focus, and longstanding partnership with the Italian healthcare system (historically the joint venture partner of MSD in vaccines via Sanofi Pasteur MSD).
• Pfizer Italia: Italian subsidiary of Pfizer Inc., operating as a multi-therapeutic-area biopharma with a major vaccines franchise (including Comirnaty and pneumococcal vaccines). Directly comparable in GTM model (medical rep–led commercialization through SSN) and overlapping vaccine and oncology portfolios.
• Novartis Farma Italia: Italian subsidiary of Novartis AG, a research-intensive biopharma with oncology, immunology, and cardiometabolic focus. Comparable in therapeutic-area breadth, R&D intensity, and SSN/hospital commercialization through Italian regulatory pricing negotiations.

Broad incumbents

• Johnson & Johnson Medical Italia: Italian operations of Johnson & Johnson, a diversified healthcare conglomerate spanning pharmaceuticals, medical devices, and consumer health. Comparable in pharmaceutical commercial scale and SSN access, with broader portfolio reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/msdsalute
• Facebookfacebook.com/msdsalute
• LinkedInlinkedin.com/company/msd-italia
• Instagraminstagram.com/msd_salute/?hl=en

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MSD (Italia) s.r.l.